Novavax (NASDAQ: NVAX) reported Q2 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $8.03 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.